ºñÀÓ»ó | ÀÓ»ó1»ó | ÀÓ»ó2»ó | ÀÓ»ó3/4»ó | ½ÃÆÇ | |
---|---|---|---|---|---|
½ÉÇ÷°ü°è Áúȯ |
SP-8416 ½ÉºÎÀü »êÇп¬ |
SP-8356 ÇãÇ÷¼º ³úÁ¹Áß, µ¿¸Æ°æÈÁõ »êÇп¬, »êÀںΠÀ¯¸Á¹ÙÀÌ¿À IPÃËÁø |
Otaplimastat ÇãÇ÷¼º ³úÁ¹Áß º¹ÁöºÎ 10´ë ƯÈ, ÀÚü°³¹ß |
ĵ¥¾Ï·Î¢ç °íÇ÷¾Ð 2Á¦ º¹ÇÕÁ¦, ÀÚü°³¹ß |
|
Otaplimastat Ãß°¡ ÀûÀÀÁõ |
ĵ¥¾Ï·Î °íÇ÷¾Ð 3Á¦ º¹ÇÕÁ¦, ÀÚü°³¹ß |
¿¡Á¦·Î¼ö¢ç °íÁöÇ÷Áõ 2Á¦ º¹ÇÕÁ¦, ÀÚü°³¹ß |
|||
SP-8257 ³Ä¡¼º ½É³úÇ÷°ü Áúȯ |
|||||
°ñÁúȯ |
ÇÏÀ̾ËÇ÷º½º¢ç °ñ°üÀý¿° »êÀںΠATC/¿ùµåŬ·¡½º Ç÷¯½º |
||||
ÇÏÀ̾Ëž¢ç °ñ°üÀý¿° »êÀںΠ¿ùµåŬ·¡½º Ç÷¯½º |
|||||
ÀÇ·á±â±â |
SP5V005 ¼ö¼ú ½Ã À¯Âø¹æÁö, Ãß°¡ ±â´É ÀÚü°³¹ß |
¸ÞµðĿư¢ç ¼ö¼ú ½Ã À¯Âø¹æÁö ÀÚü°³¹ß |
|||
°¨¿°¼º Áúȯ |
ÇÇ¶ó¸Æ½º¢ç Á¤ COVID-19 ¾à¹°ÀçâÃâ, ÀÚü°³¹ß |
ÇÇ¶ó¸Æ½º¢ç Á¤ ¸»¶ó¸®¾Æ º¹ÇÕÁ¦, ¼ºÀοë, ÀÚü°³¹ß, WHO-MMV |
|||
ÇÇ¶ó¸Æ½º¢ç °ú¸³ ¸»¶ó¸®¾Æ º¹ÇÕÁ¦, ¼Ò¾Æ¿ë, ÀÚü°³¹ß, WHO-MMV |
|||||
Ç÷§Æû±â¼ú °³¹ßÁøÀÔ |
Ư¼ö Á¦Çü ¼¹æÈ, Àú·ùÇü, Double layer formulation, Tablet in Capsule, etc. |